Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines To Treat Post-Traumatic Stress Disorder

Clearmind Medicine Inc.

Clearmind Medicine Inc.

CMND

0.00

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biopharmaceutical  company  advancing non-hallucinogenic, psychedelic-derived neuroplastogens  for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders, including AUD,  today announced  an advancement of its IP portfolio with the publication in the United States of its patent application covering a novel combination of 3,4-methylenedioxymethamphetamine ("MDMA") and N-acylethanolamines, such as palmitoylethanolamide ("PEA"), in methods of treating post-traumatic stress disorder (PTSD), anxiety, and eating disorders. The U.S. patent application was published by the United States Patent and Trademark Office (USPTO).

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.